MOESM1 of The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

Additional file 1: This file includes additional Figures of results that support and expand some of the results in the main text, but whose inclusion would detract from the main argument

MOESM1 of Incidence and admission rates for severe malaria and their impact on mortality in Africa

Additional file 1. This file includes additional methods figures and tables of results that support and expand some of the results in the main text, but whose inclusion would detract from the main argument

MOESM2 of Distribution of malaria exposure in endemic countries in Africa considering country levels of effective treatment

Additional file 2. This file includes additional Figures of results that support and expand some of the results in the main text, but whose inclusion would detract from the main argument

MOESM1 of Distribution of malaria exposure in endemic countries in Africa considering country levels of effective treatment

Additional file 1. This file includes additional Tables that support and expand some of the results in the main text, but whose inclusion would detract from the main argument

Effect of half-life of underlying efficacy on effectiveness of vaccination.

<p>The three columns correspond to distinct outcomes (uncomplicated episodes, severe malaria, and malaria-related mortality [including both direct and indirect]). The rows correspond to different deployment strategies. The horizontal axis in each graph corresponds to the half-life of the underlying effect of the vaccine. The black lines give the median relative effectiveness during the first 10 y of the program for each model, where relative effectiveness is defined as the proportion of events averted divided by the proportion of events averted by a vaccine with a 10-y half-life. The grey areas correspond to the range of this relative effectiveness for all simulations (three simulations for each model and each half-life). All simulations refer to the 20-ibpa (initial) transmission setting.</p

Effects of the assumption of zero efficacy of incomplete vaccination courses.

<p>The rows correspond to deployment strategies as defined in the main text. The relative effectiveness during the first 10 y of the program is computed as the proportion of events averted assuming zero efficacy of incomplete courses, divided by the proportion of events averted assuming the reference efficacy of incomplete courses. The minima and maxima are computed over all 14 models and three simulations for each model. All simulations refer to the 20-ibpa transmission setting.</p

Efficacy in averting clinical episodes in simulated clinical trials.

<p>The three panels correspond to different decay rates of vaccine efficacy: (A) 5-y half-life, (B) 10-y half-life, and (C) no decay. The dashed lines give the underlying efficacy. Each continuous line corresponds to a different model within the ensemble, and displays spline-smoothed estimates of efficacy in averting clinical disease. The grey area is an envelope enclosing all the simulation results. All simulations refer to the 20-ibpa transmission setting and the EPI schedule described in the <a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001157#s2" target="_blank">Methods</a>.</p

Numbers of doses of vaccine delivered by various deployment strategies over time.

<p>Numbers of doses of vaccine delivered by various deployment strategies over time.</p

Numbers of clinical episodes averted.

<p>(A) EIR = 2 ibpa, EPI vaccination. (B) EIR = 20 ibpa, EPI vaccination. (C) EIR = 2 ibpa, EPI and school vaccination, high coverage. (D) EIR = 20 ibpa, EPI and school vaccination, high coverage. (E) EIR = 2 ibpa, mass vaccination, high coverage. (F) EIR = 20 ibpa, mass vaccination, high coverage. The lines correspond to the median values of the five simulations for each model within the ensemble of the episodes averted per capita, computed from values averaged within each simulation over the full year; the grey areas are the envelopes delimited by the 2.5 and 97.5 percentiles of the simulations.</p

Simulated Entomological Inoculation Rates over time.

<p>Simulated Entomological Inoculation Rates over time.</p